Skip to main content
HR 5663 116th Congress House Health Administrative law and regulatory procedures Administrative remedies Department of Health and Human Services Drug safety, medical device, and laboratory regulation Due process and equal protection Evidence and witnesses Health technology, devices, supplies Product safety and quality Trade restrictions

Safeguarding Therapeutics Act

Introduced: January 21, 2020 Introduced by: Guthrie, Brett Republican · Kentucky See on congress.gov
 Everywhere this bill has been 29 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jan 5, 2021
Became Public Law No: 116-304.
Jan 5, 2021
Signed by President.
Dec 24, 2020
Presented to President.
Dec 10, 2020
Motion to reconsider laid on the table Agreed to without objection.
Dec 10, 2020
On motion that the House agree to the Senate amendment Agreed to without objection. (text: CR H7131)
Dec 10, 2020
Resolving differences -- House actions: On motion that the House agree to the Senate amendment Agreed to without objection.(text: CR H7131)
Dec 10, 2020
Mrs. Dingell asked unanimous consent to take the bill, H.R. 5663 from the Speaker's Table and agree to the Senate amendment. (consideration: CR H7131)
Dec 10, 2020
Mrs. Dingell asked unanimous consent that the House agree to the Senate amendment.
Dec 9, 2020
Message on Senate action sent to the House.
Dec 8, 2020
Passed Senate with an amendment by Unanimous Consent. (text of amendment in the nature of a substitute: CR S7286)
Dec 8, 2020
Passed/agreed to in Senate: Passed Senate with an amendment by Unanimous Consent.
Dec 8, 2020
Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent.
Dec 8, 2020
Measure laid before Senate by unanimous consent. (consideration: CR S7286)
Sep 22, 2020
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sep 21, 2020
Motion to reconsider laid on the table Agreed to without objection.
Sep 21, 2020
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4635)
Sep 21, 2020
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
Sep 21, 2020
DEBATE - The House proceeded with forty minutes of debate on H.R. 5663.
Sep 21, 2020
Considered under suspension of the rules. (consideration: CR H4635-4636)
Sep 21, 2020
Mrs. Dingell moved to suspend the rules and pass the bill, as amended.
Sep 17, 2020
Placed on the Union Calendar, Calendar No. 412.
Sep 17, 2020
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-512.
Jul 15, 2020
Ordered to be Reported (Amended) by Voice Vote.
Jul 15, 2020
Committee Consideration and Mark-up Session Held.
Mar 11, 2020
Subcommittee Consideration and Mark-up Session Held.
Mar 11, 2020
Ordered to be Reported by Voice Vote.
Jan 22, 2020
Referred to the Subcommittee on Health.
Jan 21, 2020
Referred to the House Committee on Energy and Commerce.
Jan 21, 2020
Introduced in House
 Plain-English summary Congressional Research Service

Safeguarding Therapeutics Act

This bill authorizes the Food and Drug Administration to destroy imported counterfeit medical devices.

What's happening now January 5, 2021

Became Public Law No: 116-304.

 Committees of jurisdiction 3